Followers | 130 |
Posts | 14996 |
Boards Moderated | 1 |
Alias Born | 06/04/2018 |
Monday, October 26, 2020 11:45:39 PM
- Data highlight the importance of early intervention with fast-acting E-selectin inhibitors to disrupt the underlying inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) - Abstracts for two of GlycoMimetics’ wholly-owned product candidates, rivipansel and...
In case you are interested GLYC - New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting
@whytestocks
Recent GLYC News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/15/2024 09:01:27 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/14/2024 08:13:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 07:55:22 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/29/2024 11:24:49 PM
- GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan • Business Wire • 07/25/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 01:30:15 PM
- GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) • Business Wire • 06/04/2024 11:00:00 AM
- GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 • Business Wire • 05/29/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:01:01 PM
- GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) • Business Wire • 05/06/2024 10:00:00 AM
- GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 • Business Wire • 04/25/2024 11:00:00 AM
- GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 • Business Wire • 03/27/2024 11:00:00 AM
- GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 • Business Wire • 03/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 02:16:05 PM
- GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference • Business Wire • 02/26/2024 12:00:00 PM
- GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 02/12/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:12 PM
- GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 • Business Wire • 01/04/2024 12:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM